Premium
Synthesis and Biological Evaluation of Nitric Oxide‐Donating Thalidomide Analogues as Anticancer Agents
Author(s) -
Wang Tao,
Zhang YiHua,
Kong XiangWen,
Lai YiSheng,
Ji Hui,
Chen YanPing,
Peng SiXun
Publication year - 2009
Publication title -
chemistry and biodiversity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.427
H-Index - 70
eISSN - 1612-1880
pISSN - 1612-1872
DOI - 10.1002/cbdv.200800014
Subject(s) - chemistry , nitric oxide , cytotoxicity , in vitro , thalidomide , cytotoxic t cell , stereochemistry , combinatorial chemistry , cell culture , pharmacology , tumor cells , biochemistry , cancer research , organic chemistry , immunology , biology , genetics , multiple myeloma
In search of more potent anticancer agents, 15 nitric oxide (NO)‐donating thalidomide analogues, 6a, 6b, 8a – 8e , and 13a – 13h , were designed and synthesized. Cytotoxicity of these compounds was evaluated in vitro against three human tumor cell lines (HepG2, A549, and PC‐3). The results indicated that 13a – 13d exhibited notable anticancer activities comparable to or stronger than that of 5‐fluorouracil (5‐FU). Structure–activity relationships were also discussed, based on the experimental data obtained. Generally, the cytotoxic activity of target compounds is closely related to the type of NO donors, and the length of the spacers connecting to NO donors also appears important for the bioactivities.